Calreticulin Is the Dominant Pro-Phagocytic Signal on Multiple Human Cancers and Is Counterbalanced by CD47

The hallmarks of cancer

Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219

Stem cells, cancer, and cancer stem cells

Reya, T., Morrison, S. J., Clarke, M. F., & Weissman, I. L. (2001) · Nature · doi:10.1038/35102167 · Cited by 9,738

Identification of human brain tumour initiating cells

Singh, S. K., Hawkins, C. E., Clarke, I. D., Squire, J. A., Bayani, J., Hide, T., Henkelman, R. M., Cusimano, M. D., & Dirks, P. B. (2004) · Nature · doi:10.1038/nature03128 · Cited by 7,564

A cell initiating human acute myeloid leukaemia after transplantation into SCID mice

Lapidot, T., Sirard, C., Vormoor, J., Murdoch, B., Hoang, T., Caceres-Cortes, J., Minden, M., Paterson, B., Caligiuri, M. A., & Dick, J. E. (1994) · Nature · doi:10.1038/367645a0 · Cited by 4,783

Calreticulin exposure dictates the immunogenicity of cancer cell death

Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216

Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data

Dai, M. (2005) · Nucleic Acids Research · doi:10.1093/nar/gni179 · Cited by 1,807

CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells

Majeti, R., Chao, M. P., Alizadeh, A. A., Pang, W. W., Jaiswal, S., Gibbs, K. D., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.045 · Cited by 1,752

CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid Phagocytosis

Jaiswal, S., Jamieson, C. H. M., Pang, W. W., Park, C. Y., Chao, M. P., Majeti, R., Traver, D. J., van Rooijen, N., & Weissman, I. L. (2009) · Cell · doi:10.1016/j.cell.2009.05.046 · Cited by 1,578

A blast from the past: clearance of apoptotic cells regulates immune responses

Savill, J., Dransfield, I., Gregory, C. D., & Haslett, C. (2002) · Nature reviews. Immunology · doi:10.1038/nri957 · Cited by 1,574

Immune surveillance of tumors

Swann, J. B., & Smyth, M. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31405 · Cited by 1,518

The Contemporary Approach to CALR-Positive Myeloproliferative Neoplasms

Mikič, T. B., Pajič, T., Zver, S., & Sever, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22073371 · Cited by 20

Perspectives on anti-CD47 antibody treatment for experimental cancer

Unanue, E. R. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1308463110 · Cited by 21

Active Role of the Necrotic Zone in Desensitization of Hypoxic Macrophages and Regulation of CSC-Fate: A hypothesis

Mehrabi, M., Amini, F., & Mehrabi, S. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00235 · Cited by 24

Tumor-associated macrophages in bladder cancer: roles and targeted therapeutic strategies

Ma, Y., Sun, Y., Guo, H., & Yang, R. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1418131 · Cited by 20

Frequency and Molecular Characteristics of Calreticulin Gene (CALR) Mutations in Patients with JAK2-Negative Myeloproliferative Neoplasms

Wojtaszewska, M. L., Iwoła, M., & Lewandowski, K. C. (2014) · Acta Haematologica · doi:10.1159/000366263 · Cited by 20

Blockade of CD47 or SIRPα: a new cancer immunotherapy

Murata, Y., Saito, Y., Kotani, T., & Matozaki, T. (2020) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2020.1811855 · Cited by 20

Structural analysis and binding sites of inhibitors targeting the CD47/SIRPα interaction in anticancer therapy

Huang, B. Y., Bai, Z., Ye, X., Zhou, C., Xie, X., Zhong, Y., Lin, K., & Ma, L. (2021) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2021.09.036 · Cited by 20

Preclinical characterization of the novel anti-SIRPα antibody BR105 that targets the myeloid immune checkpoint

Wu, Z.-H., Li, N., Mei, X.-F., Chen, J., Wang, X., Guo, T., Chen, G., Nie, L., Chen, Y., Jiang, M.-Z., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004054 · Cited by 19

A phase II multi-arm study of magrolimab combinations in patients with relapsed/refractory multiple myeloma

Paul, B. A., Liedtke, M., Khouri, J., Rifkin, R. M., Gandhi, M. D., Kin, A. D., Levy, M. Y., Silbermann, R. W., Cottini, F., Sborov, D. W., et al. (2023) · Future Oncology · doi:10.2217/fon-2022-0975 · Cited by 20

TP53 in AML and MDS: The new (old) kid on the block

Marks, J. A., Wang, X., Fenu, E. M., Bagg, A., & Lai, C. (2023) · Blood Reviews · doi:10.1016/j.blre.2023.101055 · Cited by 20

NIR-II Light-driven genetically edited nanoparticles with inherent CRT-inducing capability for macrophage-mediated immunotherapy

Huang, Q., Su, M., Zhao, L., Zhang, Z., Zhang, Y., Yang, X., & Wang, J. (2023) · Nano Today · doi:10.1016/j.nantod.2023.101857 · Cited by 20

Oncolytic virus and tumor-associated macrophage interactions in cancer immunotherapy

Lecoultre, M., Walker, P. R., & Helali, A. E. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01443-8 · Cited by 23

CD47 blockade reduces the pathologic features of experimental cerebral malaria and promotes survival of hosts with Plasmodium infection

Dulgeroff, L. B. T., Oakley, M. S., Tal, M. C., Yiu, Y. Y., He, J. Q., Shoham, M., Majam, V., Okoth, W. A., Malla, P., Kumar, S., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1907653118 · Cited by 20

CALR mutations screening in wild type JAK2V617F and MPLW515K/L Brazilian myeloproliferative neoplasm patients

Nunes, D. P. T., de Lima, L. T., Chauffaille, M. D. L., Mitne‐Neto, M., dos Santos, M. T., Cliquet, M. G., & Guerra‐Shinohara, E. M. (2015) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2015.07.005 · Cited by 20

Disruption of CD47-SIRPα signaling restores inflammatory function in tumor-associated myeloid-derived suppressor cells

Zimarino, C., Moody, W., Davidson, S. E., Munir, H., & Shields, J. D. (2024) · iScience · doi:10.1016/j.isci.2024.109546 · Cited by 19

Bispecific Antibody Targeting VEGF/TGF‐β Synergizes with Local Radiotherapy: Turning Tumors from Cold to Inflamed and Amplifying Abscopal Effects

Lyu, L., Yi, M., Chen, J., Zhang, J., Ma, X., Zhang, X., Zeng, L., Xue, Y., Wen, H., Deng, Y., et al. (2025) · Advanced Science · doi:10.1002/advs.202501819 · Cited by 19

Increased CD47 and MHC Class I Inhibitory Signals Expression in Senescent CD1 Primary Mouse Lung Fibroblasts

Hernández‐Mercado, E., Prieto‐Chávez, J. L., Arriaga‐Pizano, L., Hernández-Gutiérrez, S., Mendlovic, F., Königsberg, M., & López‐Díazguerrero, N. E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221910215 · Cited by 19

Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia

Cluzeau, T., Loschi, M. L., Fenaux, P., Komrokji, R. S., & Sallman, D. A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms221810105 · Cited by 20

Engagement of CD99 Activates Distinct Programs in Ewing Sarcoma and Macrophages

Manara, M. C., Manferdini, C., Cristalli, C., Carrabotta, M., Santi, S., Feo, A. D., Caldoni, G., Pasello, M., Landuzzi, L., Lollini, P., et al. (2023) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-23-0440 · Cited by 23

Targeted therapies prime oncogene-driven lung cancers for macrophage-mediated destruction

Vaccaro, K., Allen, J., Whitfield, T. W., Maoz, A., Reeves, S., Velarde, J., Yang, D., Meglan, A., Ribeiro, J., Blandin, J., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci169315 · Cited by 19

Combating HER2-overexpressing breast cancer through induction of calreticulin exposure by Tras-Permut CrossMab

Zhang, F., Zhang, J., Liu, M., Zhao, L., Linghu, R., Feng, F., Gao, X., Jiao, S., Zhao, L., Hu, Y., et al. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.994391 · Cited by 19

Comparative Analysis of Immune Checkpoint Molecules and Their Potential Role in the Transmissible Tasmanian Devil Facial Tumor Disease

Flies, A. S., Blackburn, N. B., Lyons, A. B., Hayball, J. D., & Woods, G. M. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00513 · Cited by 18

Induction of Immunogenic Cell Death in Lymphoma Cells by Wharton’s Jelly Mesenchymal Stem Cell Conditioned Medium

Lin, D. H., Biswas, A., Choolani, M. A., Fong, C., & Bongso, A. (2017) · Stem Cell Reviews and Reports · doi:10.1007/s12015-017-9767-8 · Cited by 18

Trend in biodegradable porous nanomaterials for a nticancer drug delivery

Le, B. Q. G., & Đoàn, T. L. H. (2023) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1874 · Cited by 19

Protein signatures correspond to survival outcomes of AJCC stage III melanoma patients

Mactier, S., Alexander, K. L., Wang, P., Crossett, B., Pupo, G. M., Kohnke, P. L., Thompson, J. F., Scolyer, R. A., Yang, J. Y. H., Mann, G. J., et al. (2014) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12290 · Cited by 18

Novel immunotherapy for gastric cancer: targeting the CD47–SIRPα axis

Ooki, A., Osumi, H., Shimozaki, K., & Yamaguchi, K. (2025) · Cancer and Metastasis Reviews · doi:10.1007/s10555-025-10269-z · Cited by 19

Anti-leukemia effect associated with down-regulated CD47 and up-regulated calreticulin by stimulated macrophages in co-culture

Hassan, E. M., Walker, G. C., Wang, C., & Zou, S. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02728-z · Cited by 18

Soluble extracellular domains of human SIRPα and CD47 expressed in Escherichia coli enhances the phagocytosis of leukemia cells by macrophages in vitro

Yan, L., Yan, X.-Q., Yang, F., Yang, X., Jiang, X., Zhao, X., Zhu, B.-K., Liu, L., Qin, H., Liang, Y., et al. (2012) · Protein Expression and Purification · doi:10.1016/j.pep.2012.07.002 · Cited by 18

Hypoxia induces immunogenic cell death of cancer cells by enhancing the exposure of cell surface calreticulin in an endoplasmic reticulum stress‑dependent manner

Han, Y. K., Park, G., Bae, M., Kim, J., Jo, W. S., & Lee, C. (2019) · Oncology Letters · doi:10.3892/ol.2019.10986 · Cited by 18

Differential Effect of Non-Thermal Plasma RONS on Two Human Leukemic Cell Populations

Mohamed, H., Gebski, E. B., Reyes, R., Beane, S., Wigdahl, B. L., Krebs, F. C., Stapelmann, K., & Miller, V. (2021) · Cancers · doi:10.3390/cancers13102437 · Cited by 18

Mini-chaperones

Bolhassani, A., & Rafati, S. (2012) · Human Vaccines & Immunotherapeutics · doi:10.4161/hv.22248 · Cited by 18

HSP90 inhibition acts synergistically with heat to induce a pro-immunogenic form of cell death in colon cancer cells

Mouratidis, P., & ter Haar, G. (2021) · International Journal of Hyperthermia · doi:10.1080/02656736.2021.1983036 · Cited by 17

Targeting Myeloid Checkpoint Molecules in Combination With Antibody Therapy: A Novel Anti-Cancer Strategy With IgA Antibodies?

Chan, C., Lustig, M., Baumann, N., Valerius, T., van Tetering, G., & Leusen, J. H. W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.932155 · Cited by 17

The role of dendritic cells in radiation-induced immune responses

Kaur, A. P., Alice, A. F., Crittenden, M. R., & Gough, M. J. (2023) · International review of cytology · doi:10.1016/bs.ircmb.2023.02.002 · Cited by 18

Review and prospect of immune checkpoint blockade therapy represented by PD-1/PD-L1 in the treatment of clear cell renal cell carcinoma

Ge, W., Song, S., Qi, X., Chen, F., Che, X., Sun, Y., Wang, J., Li, X., Liu, N., Wang, Q., et al. (2023) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.027942 · Cited by 18

Myeloid MyD88 restricts CD8+ T cell response to radiation therapy in pancreatic cancer

Medler, T. R., Blair, T. C., Alice, A. F., Dowdell, A. K., Piening, B., Crittenden, M. R., & Gough, M. J. (2023) · Scientific Reports · doi:10.1038/s41598-023-35834-w · Cited by 18

WITHDRAWN: Hypericin-based Photodynamic Therapy Induces a Tumor-Specific Immune Response and an Effective DC-based cancer Immunotherapy

Zheng, Y., Yin, G., Le, V., Zhang, A., Lü, Y., Yang, M., Fei, Z., & Liu, J. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.01.036 · Cited by 17

Head and neck tumor cells treated with hypofractionated irradiation die via apoptosis and are better taken up by M1-like macrophages

Wedekind, H., Walz, K., Buchbender, M., Rieckmann, T., Strasser, E. F., Grottker, F., Fietkau, R., Frey, B., Gaipl, U. S., & Rückert, M. (2021) · Strahlentherapie und Onkologie · doi:10.1007/s00066-021-01856-4 · Cited by 16

Design of Light‐Activated Nanoplatform through Boosting “Eat Me” Signals for Improved CD47‐Blocking Immunotherapy

Lu, Y., Gong, Y., Zhu, X., Dong, X., Zhu, D., & Ma, G. (2022) · Advanced Healthcare Materials · doi:10.1002/adhm.202102712 · Cited by 16

Role of CD47-SIRPα Checkpoint in Nanomedicine-Based Anti-Cancer Treatment

Liao, H., & Niu, C. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.887463 · Cited by 16

Checkpoint Inhibitors in Acute Myeloid Leukemia

Damiani, D., & Tiribelli, M. (2023) · Biomedicines · doi:10.3390/biomedicines11061724 · Cited by 16

Tumor Microenvironment Landscape of NSCLC Reveals Resistance Mechanisms for Programmed Death-Ligand 1 Blockade After Chemoradiotherapy: A Multicenter Prospective Biomarker Study (WJOG11518L:SUBMARINE)

Haratani, K., Nakamura, A., Mamesaya, N., Mitsuoka, S., Yoneshima, Y., Saito, R., Tanizaki, J., Fujisaka, Y., Hata, A., Tsuruno, K., et al. (2023) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2023.06.012 · Cited by 17

Dual Role of Vitamin C-Encapsulated Liposomal Berberine in Effective Colon Anticancer Immunotherapy

Mianowska, M., Zaremba-Czogalla, M., Zygmunt, A., Mahmud, M., Süss, R., & Gubernator, J. (2023) · Pharmaceuticals · doi:10.3390/ph17010005 · Cited by 16

Monoclonal Antibodies in Acute Myeloid Leukemia—Are We There Yet?

Abaza, Y., & Fathi, A. T. (2022) · The Cancer Journal · doi:10.1097/ppo.0000000000000577 · Cited by 16

Targeting CXCR4 and CD47 Receptors: An Overview of New and Old Molecules for a Biological Personalized Anticancer Therapy

Leo, M., & Sabatino, L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232012499 · Cited by 14

A sequence-specific DNA binding small molecule triggers the release of immunogenic signals and phagocytosis in a model of B-cell lymphoma

Kang, J. S., & Dervan, P. B. (2015) · Quarterly Reviews of Biophysics · doi:10.1017/s0033583515000104 · Cited by 15

BNIP3 modulates the interface between B16-F10 melanoma cells and immune cells

Romano, E., Rufo, N., Korf, H., Mathieu, C., Garg, A. D., & Agostinis, P. (2018) · Oncotarget · doi:10.18632/oncotarget.24815 · Cited by 15

Tumor mechanisms of resistance to immune attack

Zahavi, D. J., & Weiner, L. M. (2019) · Progress in molecular biology and translational science · doi:10.1016/bs.pmbts.2019.03.009 · Cited by 15

Using Preclinical Data to Design Combination Clinical Trials of Radiation Therapy and Immunotherapy

Gough, M. J., Sharon, S., Crittenden, M. R., & Young, K. H. (2020) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2019.12.002 · Cited by 15

Radiation and Immunotherapy in Upper Gastrointestinal Cancers: The Current State of Play

Donlon, N. E., Power, R. F., Hayes, C., Davern, M., Reynolds, J. V., & Lysaght, J. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031071 · Cited by 15

The role of hypoxia-inducible factors in breast cancer stem cell specification

Fath, M. K., Garousi, S., Mottahedi, M., Ghasemzadeh, N., Salmani, K., Olfati, F., Saeed, M. B., Sotoudeh, S., & Barati, G. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154349 · Cited by 15

Putting the brakes on anticancer therapies: suppression of innate immune pathways by tumor-associated myeloid cells

Jinushi, M., Yagita∥, H., Yoshiyama, H., & Tahara, H. (2013) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2013.06.001 · Cited by 15

Calreticulin is a novel independent prognostic factor for oral squamous cell carcinoma

Harada, K., Takenawa, T., Ferdous, T., Kuramitsu, Y., & Ueyama, Y. (2017) · Oncology Letters · doi:10.3892/ol.2017.6062 · Cited by 15

Conventional amphotericin B elicits markers of immunogenic cell death on leukemic blasts, mediates immunostimulatory effects on phagocytic cells, and synergizes with PD-L1 blockade

Kofla, G., Radecke, C., Frentsch, M., Walther, W., Stintzing, S., Riess, H., Bullinger, L., & Na, I. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2068109 · Cited by 14

Efficient polymeric nanoparticles for RNAi in macrophage reveal complex effects on polarization markers upon knockdown of STAT3/STAT6

Walther, M., Jenke, R., Aigner, A. M., & Ewe, A. (2024) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2024.114232 · Cited by 14

In situ TLR7 activation with biocompatible injectable hydrogel for synergistic chemo-immunotherapy

Feng, C., Xiao, S., Mu, M., Wang, X., Yu, W., Pan, S., Li, H., Fan, R., Han, B. R., & Guo, G. F. (2025) · Journal of Material Science and Technology · doi:10.1016/j.jmst.2025.02.088 · Cited by 14

Morphometric analysis of immunoselection against hyperploid cancer cells

Bloy, N., Sauvat, A., Chaba, K., Buqué, A., Humeau, J., Pedro, J. M. B., Bui, J. D., Kepp, O., Kroemer, G., & Senovilla, L. (2015) · Oncotarget · doi:10.18632/oncotarget.5400 · Cited by 15

Could ER Stress Be A Major Link Between Oxidative Stress And Autoimmunity In Vitiligo?

Mansuri, M. S., & Singh, M. (2014) · Journal of Pigmentary Disorders · doi:10.4172/2376-0427.1000123 · Cited by 14

Calreticulin mutation does not contribute to disease progression in essential thrombocythemia by inhibiting phagocytosis

Daitoku, S., Takenaka, K., Yamauchi, T., Yurino, A., Jinnouchi, F., Nunomura, T., Eto, T., Kamimura, T., Higuchi, M., Harada, N., et al. (2016) · Experimental Hematology · doi:10.1016/j.exphem.2016.05.001 · Cited by 14

Immunogenicity of Externally Activated Nanoparticles for Cancer Therapy

Sahin, O., Ashokkumar, M., Ajayan, P. M., & Krishnan, S. (2020) · Cancers · doi:10.3390/cancers12123559 · Cited by 15

CD47 Promotes Autoimmune Valvular Carditis by Impairing Macrophage Efferocytosis and Enhancing Cytokine Production

Meier, L. A., Faragher, J. L., Osinski, V., Auger, J. L., Voeller, R. K., Marath, A., & Binstadt, B. A. (2022) · The Journal of Immunology · doi:10.4049/jimmunol.2100903 · Cited by 15

Susceptibility of rhabdomyosarcoma cells to macrophage-mediated cytotoxicity

Herrmann, D., Seitz, G., Fuchs, J., & Armeanu–Ebinger, S. (2012) · OncoImmunology · doi:10.4161/onci.18612 · Cited by 14

CD47 receptor as a primary target for cancer therapy

Ratnikova, N. M., Lezhnin, Y. N., Frolova, E. I., Kravchenko, J. E., & Chumakov, S. P. (2017) · Molecular Biology · doi:10.1134/s0026893317010150 · Cited by 14

Conditioning neoadjuvant therapies for improved immunotherapy of cancer

Benson, Z., Manjili, S. H., Habibi, M., Guruli, G., Toor, A. A., Payne, K. K., & Manjili, M. H. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.08.007 · Cited by 14

DAMPening Tumor Immune Escape: The Role of Endoplasmic Reticulum Chaperones in Immunogenic Chemotherapy

Cifrić, S., Turi, M., Folino, P., Clericuzio, C., Barello, F., Maciel, T., Anderson, K. C., & Gullà, A. (2024) · Antioxidants and Redox Signaling · doi:10.1089/ars.2024.0558 · Cited by 12

Polyinosinic/Polycytidylic Lipid Nanoparticles Enhance Immune Cell Infiltration and Improve Survival in the Glioblastoma Mouse Model

Brüßeler, M., Zam, A., Moreno-Zafra, V., Rouatbi, N., Hassuneh, O. W. M., Marrocu, A., Liam‐Or, R., Abdel‐Bar, H. M., Walters, A. A., & Al‐Jamal, K. T. (2024) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00875 · Cited by 14

Quantitative Proteomics Analysis of the cAMP/Protein Kinase A Signaling Pathway

Guo, Y., Wilderman, A. S., Zhang, L., Taylor, S. S., & Insel, P. A. (2012) · Biochemistry · doi:10.1021/bi301282k · Cited by 13

Ubc7/Ube2g2 ortholog in Entamoeba histolytica: connection with the plasma membrane and phagocytosis

Kumari, R., Gupta, P., & Tiwari, S. (2018) · Parasitology Research · doi:10.1007/s00436-018-5842-6 · Cited by 13

Investigation of Gene Expressions of Myeloma Cells in the Bone Marrow of Multiple Myeloma Patients by Transcriptome Analysis

Sarıman, M., Abacı, N., Ekmekçi, S. S., Çakiris, A., Paçal, F. P., Üstek, D., Ayer, M., Yenerel, M. N., Beşışık, S. K., Çefle, K., et al. (2018) · Balkan Medical Journal · doi:10.4274/balkanmedj.2018.0356 · Cited by 13

A Cell-Specific Nuclear Factor-Kappa B–Activating Gene Expression Strategy for Delivering Cancer Immunotherapy

Wang, D., Dai, W., & Wang, J. (2018) · Human Gene Therapy · doi:10.1089/hum.2018.093 · Cited by 11

A novel calreticulin-related molecule that interacts with bacteria and enhances host resistance against bacterial infection in black rockfish, Sebastes schlegeli

Wang, G., Li, Z., Guo, E., Wang, J., Zhang, M., & Hu, Y. (2019) · Fish & Shellfish Immunology · doi:10.1016/j.fsi.2019.08.043 · Cited by 13

Targeting Menin and CD47 to Address Unmet Needs in Acute Myeloid Leukemia

Matthews, A. H., Pratz, K. W., & Carroll, M. P. (2022) · Cancers · doi:10.3390/cancers14235906 · Cited by 13

Evolving Evidence of Calreticulin as a Pharmacological Target in Neurological Disorders

Kotian, V., Sarmah, D., Kaur, H., Kesharwani, R., Verma, G., Mounica, L., Veeresh, P., Kalia, K., Borah, A., Wang, X., et al. (2019) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.9b00158 · Cited by 12

The overall potential of CD47 in cancer immunotherapy: with a focus on gastrointestinal tumors

Tzatzarakis, E., Hissa, B., Reißfelder, C., & Schölch, S. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1689820 · Cited by 13

Distinct roles in phagocytosis of the early and late increases of cell surface calreticulin induced by oxaliplatin

Matsusaka, K., Azuma, Y., Kaga, Y., Uchida, S., Takebayashi, Y., Tsuyama, T., & Tada, S. (2022) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2022.101222 · Cited by 13

Maplirpacept: a CD47 decoy receptor with minimal red blood cell binding and robust anti-tumor efficacy

Krishnamoorthy, M., Seelige, R., Brown, C. R., Chau, N., Viller, N. N., Johnson, L. D. S., Linderoth, E., Wang, J. C. Y., Dillon, C. P., Abayasiriwardana, K. S., et al. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1518787 · Cited by 12

Bone marrow microenvironment in myelodysplastic neoplasms: insights into pathogenesis, biomarkers, and therapeutic targets

Bahmani, F., Shayanmanesh, M., Safari, M., Alaei, A., Pouriafar, Y., Rasti, Z., Zaker, F., Rostami, S., Damerchiloo, F., & Safa, M. (2025) · Cancer Cell International · doi:10.1186/s12935-025-03793-z · Cited by 12

STAT3 inhibition in combination with CD47 blockade inhibits osteosarcoma lung metastasis

Shrestha, P., Shrestha, R., Zhou, Y. L., Zielinski, R. J., Priebe, W., & Kleinerman, E. S. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1608375 · Cited by 13

Two cancer stem cell-targeted therapies in clinical trials as viewed from the standpoint of the cancer stem cell model

Caras, I. W. (2020) · Stem Cells Translational Medicine · doi:10.1002/sctm.19-0424 · Cited by 12

Targeting the cluster of differentiation 47/signal-regulatory protein alpha axis in myeloid malignancies

Wang, C., & Sallman, D. A. (2021) · Current Opinion in Hematology · doi:10.1097/moh.0000000000000691 · Cited by 12

miR-aculous new avenues for cancer immunotherapy

Tang, W. W., Bauer, K. M., Barba, C., Ekiz, H. A., & O’Connell, R. M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.929677 · Cited by 13

Immunotherapy combined with radiotherapy to reverse immunosuppression in microsatellite stable colorectal cancer

Wu, C., Shao, Y., & Gu, W. (2023) · Clinical & Translational Oncology · doi:10.1007/s12094-023-03091-y · Cited by 13

Combining in Situ Vaccination and Immunogenic Apoptosis to Treat Cancer

Kalami, A., Shahgolzari, M., Khosroushahi, A. Y., & Fiering, S. (2023) · Immunotherapy · doi:10.2217/imt-2022-0137 · Cited by 12

Two faces of ET: CALR and JAK2

Chao, M. P., & Gotlib, J. R. (2014) · Blood · doi:10.1182/blood-2014-01-547596 · Cited by 12

Biomarker Predictors for Immunotherapy Benefit in Breast: Beyond PD-L1

James, J. L., & Balko, J. M. (2019) · Current Breast Cancer Reports · doi:10.1007/s12609-019-00331-5 · Cited by 11

Hyperthermic intraperitoneal chemotherapy enhances antitumor effects on ovarian cancer through immune-mediated cancer stem cell targeting

Wu, C.-C., Hsu, Y.-T., & Chang, C. (2021) · International Journal of Hyperthermia · doi:10.1080/02656736.2021.1945688 · Cited by 12

CD (Cluster of Differentiation)

Vohr, H.-W. (2015) · Springer eBooks · doi:10.1007/978-3-642-54596-2_200215 · Cited by 13

Effects of a humanized CD47 antibody and recombinant SIRPα proteins on triple negative breast carcinoma stem cells

Kaur, S., Reginauld, B., Razjooyan, S., Phi, T., SINGH, S. P., Meyer, T. J., Cam, M. C., & Roberts, D. D. (2024) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2024.1356421 · Cited by 11

Oral squamous cell carcinomas drive monocytes into immunosuppressive CD25+CD163+CD206+ macrophages

Pelaez-Prestel, H. F., Gonzalez-Martin, F., Ras-Carmona, A., Rocha, A., Cabañas, C., Lafuente, E. M., & Reche, P. A. (2024) · Oral Oncology · doi:10.1016/j.oraloncology.2024.107078 · Cited by 11

Microglia membrane-mediated trans-blood-brain barrier prodrug micelles enhance phagocytosis for glioblastoma chemo-immunotherapy

Li, S., Zhang, J., Yu, T., Song, G., Ke, J., Wang, K., Xu, Y., Hong, Y., Meng, T., Hong, Y. K., et al. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.12.059 · Cited by 11

Phagocytosis‐Activating Nanocomplex Orchestrates Macrophage‐Mediated Cancer Immunotherapy

Huang, H., Tong, Q., Zhang, J., Miao, W., Yu, H.-H., Wang, J., Shen, S., & Du, J. (2025) · Advanced Materials · doi:10.1002/adma.202500982 · Cited by 11

Macrophages release neuraminidase and cleaved calreticulin for programmed cell removal

Banuelos, A. M., Baez, M., Zhang, A., Yılmaz, L., Kasberg, W., Volk, R. F., Georgeos, N., Koren, E., Le, U., Burden, A. T., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2426644122 · Cited by 11

Animal Models and Their Role in Imaging-Assisted Co-Clinical Trials

Peehl, D. M., Badea, C. T., Chenevert, T. L., Daldrup-Link, H. E., Ding, L., Dobrolecki, L. E., Houghton, A. M., Kinahan, P. E., Kurhanewicz, J. V., Lewis, M. T., et al. (2023) · Tomography · doi:10.3390/tomography9020053 · Cited by 11

Noncanonical roles of the immune system in eliciting oncogene addiction

Casey, S. C., Bellovin, D. I., & Felsher, D. W. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2013.02.003 · Cited by 11

Immune regulation of therapy-resistant niches: emerging targets for improving anticancer drug responses

Jinushi, M. (2014) · Cancer and Metastasis Reviews · doi:10.1007/s10555-014-9501-9 · Cited by 11

Combining ADCs with Immuno-Oncology Agents

Müller, P., Rios‐Doria, J., Harper, J. W., & Cao, A. (2018) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-78154-9_2 · Cited by 11

The evolution of epigenetic therapy in myelodysplastic syndromes and acute myeloid leukemia

Gonzalez‐Lugo, J. D., Chakraborty, S., Verma, A., & Shastri, A. (2020) · Seminars in Hematology · doi:10.1053/j.seminhematol.2020.12.003 · Cited by 11

Preparation and evaluation of dabrafenib-loaded, CD47-conjugated human serum albumin-based nanoconstructs for chemoimmunomodulation

Pham, L. M., Poudel, K., Phung, C. D., Nguyen, T. T., Pandit, M., Nguyen, H. T., Chang, J., Jin, S. G., Jeong, J., Ku, S., et al. (2021) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2021.112093 · Cited by 11

CD47 limits antibody dependent phagocytosis against non-malignant B cells

Gallagher, S., Turman, S., Lekstrom, K. J., Wilson, S. C., Herbst, R., & Wang, Y. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.01.022 · Cited by 11

Normal and Neoplastic Stem CellsPreprint

McCracken, M. N., George, B. M., Kao, K. S., Marjon, K. D., Raveh, T., & Weissman, I. L. (2016) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2016.81.030965 · Cited by 11

Macrophages eat cancer cells using their own calreticulin as a guide: Roles of TLR and Btk

Feng, M., Chen, J. Y., Weissman-Tsukamoto, R., Volkmer, J.-P., Ho, P. Y., McKenna, K. M., Cheshier, S. H., Zhang, M., Ring, N. G., Gip, P., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1424907112 · Cited by 253

The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors

Willingham, S. B., Volkmer, J.-P., Gentles, A. J., Sahoo, D., Dalerba, P. D., Mitra, S. S., Wang, J., Contreras-Trujillo, H., Martin, R. K., Cohen, J. D., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1121623109 · Cited by 1,706

A Calreticulin Tail: C-terminal Mutants of Calreticulin Allow Cancer Cells to Evade Phagocytosis

Kaur, A., & Raghavan, M. (2020) · Molecular Cell · doi:10.1016/j.molcel.2020.01.024 · Cited by 5

CD47 masks pro-phagocytic ligands in cis on tumor cells to suppress antitumor immunity

Tang, Z.-H., Zhong, M., Qian, J., Galindo, C. C., Davidson, D., Li, J., Zhao, Y., Hui, E., & Veillette, A. (2023) · Nature Immunology · doi:10.1038/s41590-023-01671-2 · Cited by 66

The Macrophage ‘Do not eat me’ signal, CD47, is a clinically validated cancer immunotherapy target

Takimoto, C. H. M., Chao, M. P., Gibbs, C., Mccamish, M. A., Liu, J., Chen, J. Y., Majeti, R., & Weissman, I. L. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz006 · Cited by 128